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Systems capable of residing for prolonged periods of time in the gastric cavity have
transformed our ability to diagnose and treat patients. Gastric resident systems for drug
delivery, ideally need to be: ingestible, be able to change shape or swell to ensure prolonged
gastric residence, have the mechanical integrity to withstand the forces associated with
gastrointestinal motility, be triggerable to address any side effects, and be drug loadable and
release drug over a prolonged period of time. Materials that have been primarily utilized for
these applications have been largely restricted to thermoplastics and thermosets. Here we
describe a novel set of materials, triggerable tough hydrogels, meeting all these requirement,
supported by evaluation in a large animal model and ultimately demonstrate the potential of
triggerable tough hydrogels to serve as prolonged gastric resident drug depots. Triggerable
tough hydrogels may be applied in myriad of applications, including bariatric interventions,
drug delivery, and tissue engineering.
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Devices with the ability to reside in the gastric cavity havebeen applied for diagnosis1–3 and treatment interventionsin humans4–7. The materials used for their fabrication
have been largely limited to thermoplastic and thermosets8–10.
Expanding the repertoire of materials available for system fabri-
cation stands to expand the potential set of applications by
enabling greater compatibility with gastrointestinal (GI) tissues,
and, moreover, potentially imparting signiﬁcantly improved
safety. When considering future development of novel orally
administered systems for prolonged drug release, a key set of
elements needs to be considered to ensure safety and potential
efﬁcacy of such systems, which are destined to reside in the
gastric cavity11–13. These include dosage forms in a form factor
compatible with ingestion and subsequent shape change to enable
gastric residence and prevent passage through the pylorus
(the combination of these two elements is analogous to the “ship
in the bottle” problem), triggerable elements, which can induce
controlled breakage of the dosage form, which can be either
administered or are induced by virtue of anatomic location,
mechanical, and material properties to ensure stability and
integrity in the GI environment, and the ability to be loaded with
drug and release drug in a controlled sustained manner.
One potential set of materials with enhanced biocompatibility
are hydrogels because of their softness, which can potentially
minimize mucosal damage, low polymer content that may reduce
the side effects of materials as well as maximize the capacity for
dehydration and rehydration in form factors compatible with
ingestion and subsequent gastric retention upon swelling,
and release drugs in controllable manners14–17. Conventional
hydrogels though generally suffer from being weak and, therefore,
can be easily broken by the signiﬁcant compressive and shearing
forces of the GI tract limiting their stability in this environment18.
This is exempliﬁed by the application of high viscosity grade
cellulose polymers, polyacrylic acid, polyacrylates, poly-
acrylamides, and polyethers, which have been applied to
extending release of drugs on the order of 12–16 h19. Though
these systems can provide extension of drug release, they have
only enabled the extension of release by hours20. A set of mate-
rials with the mechanical properties capable of potentially sur-
viving the gastric environment are tough hydrogels. Though
signiﬁcant advancement has been made in fabricating hydrogels
with tougher characteristics, including double-network21–25,
topological26–30, and nanocomposite hydrogels31–34, these gels
lack the capacity to be triggered to dissolve in physiological
environments, an important property to ensure the maximal
safety and removal of such a system that could reside in the
gastric cavity for multiple days. Long-term gastric resident
systems can be associated with gastric outlet obstruction and/or
the development of an allergic reaction could ensue from a gastric
drug depot. These complications would require immediate
clinical intervention and therefore a system that can be triggered
to dissolve and thereby enable passage through the GI tract could
have signiﬁcant advantages over ones without the capacity
for triggering where a procedural intervention-like surgery or
endoscopy would otherwise be required for removal. Therefore,
one essential aspect of safety lies in the ability to trigger the
dissolution and controlled fracture of the material to enable rapid
transit through the GI tract.
Here we describe a novel set of materials, triggerable tough
hydrogels (TTHs), containing up to ~90% water enabling
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Fig. 1 TTH platform and synthesis approach. a Gastric resident dosage forms for prolonged drug delivery. b TTH dosage form concept and synthesis design.
TTHs consist of two types of alginate and polyacrylamide networks that are intertwined, and separately crosslinked by stimuli-responsive Ca2+ ionic and
disulﬁde bonds, which can be dissolved into solution with a biocompatible chelator and reducing agent
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signiﬁcant shrinkage and swelling to address the “ship in the
bottle” challenge. These gels demonstrate stability in normal
gastric environments and furthermore can be triggered to dissolve
rapidly with biocompatible agents, enabling the development of
gastric devices with precisely controlled residence times. We
further demonstrate a proof-of-concept gastric resident drug
delivery system from these materials in a large animal model.
Speciﬁcally, the TTHs consist of two types of polymeric
networks that are intertwined and separately crosslinked by
stimuli-responsive bonds, which can be triggered to dissolve
into solution with biocompatible agents on demand. Given
the tough and triggerable properties of these hydrogels, we
anticipate their application in a broad set of GI biomedical
applications.
Results
Preparation and characterization of TTHs. TTHs consisting of
alginate and polyacrylamide networks are crosslinked by
ionic Ca2+ and disulﬁde bonds, respectively (Fig. 1). Alginate is a
linear copolymer comprised of blocks of α-L-guluronic acid, β-D-
mannuronic acid, or alternating α-L-guluronic and β-D-man-
nuronic acids. Divalent Ca2+ cations can crosslink alginate
by simultaneously associating with carboxylic groups in the α-L-
guluronic acid blocks from different alginate chains, forming an
ionically crosslinked network in water21. By contrast, the poly-
acrylamide network can be formed by aqueous radical poly-
merization of acrylamide using a bifunctional monomer as the
crosslinker. Since alginate and polyacrylamide networks are
separately crosslinked, stimuli-responsive ionic and disulﬁde
bonds can be incorporated making the gels susceptible to
degradation by biocompatible chelators and reducing agents,
TTHs can be de-crosslinked and dissolved into solution accord-
ingly. Alginate and polyacrylamide were selected given their well-
recognized biocompatibility and broad biomedical application35.
TTHs were fabricated by a simple one-step method. We
dissolved all ingredients needed to form the two networks in
deionized water, including sodium alginate and an ionic cross-
linker of calcium sulfate for the ionically crosslinked alginate, as
well as acrylamide, crosslinking monomer N,N′-bis(acryloyl)
cystamine, thermo-initiator of ammonium persulfate, and poly-
merization accelerator of N,N,N′,N′-tetramethylethylenediamine
for the disulﬁde crosslinked polyacrylamide. The mixture was
heated to 50 °C for 1 h and then left in a humid box for 1 day.
The unreacted ingredients were puriﬁed by continuous
extraction with water demonstrating elimination of the acryla-
mide monomer (Supplementary Fig. 1). Details of the synthesis
and characterization of TTHs are described in the
Supplementary Information.
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Fig. 2 Physical characterization of TTHs. a Photographs of a TTH strip stretched to 14 times its initial length and subsequently coiled and twisted, and a
TTH cuboid-resisted slicing with a blade. Scale bar: 1 cm. b Compressive stress-strain curves of the TTH, alginate, and polyacrylamide gels with
same amounts of alginate or polyacrylamide to the TTH. c Tensile stress-strain curves of the TTH, alginate, and polyacrylamide gels stretched to breaking.
d Plot of volume variation (Vt/V0) of the TTH vs. the incubation time at 37 °C. e Plot of the maximum compressive stress of the TTH as a function of the
incubation time in SGF at 37 °C. f Plot of diameter variation of the cylindrical dehydrated TTH vs. the incubation time at 37 °C. Error bars show standard
deviation (n= 3)
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The TTH synthesized had a water content of 87%, was highly
stretchable, ﬂexible, and could not be easily cut with a
blade (Fig. 2a). It achieved a maximum compressive stress of
3.78± 0.26 MPa that was 14 and 32 times higher than the
hydrogels composed of polyacrylamide (0.275± 0.033MPa)
or alginate (0.121± 0.017MPa) alone (Fig. 2b). The tensile
strength and fracture strain were, respectively, 149± 11 kPa and
14.6± 1.3 for the TTH, 6.2± 0.8 kPa and 5.0± 0.6 for the
polyacrylamide gel, and 4.2± 0.7 kPa and 1.9± 0.3 for the
alginate gel (Fig. 2c). The energy dissipation of the TTH was
further tested by loading-unloading experiments, showing that
the TTH dissipated energy effectively, as veriﬁed by the notable
hysteresis, while the permanent deformation after unloading was
negligible, as demonstrated by loading several samples to large
values of stretch before unloading (Supplementary Fig. 2).
We next studied the swelling behavior and variation
of mechanical properties of TTHs in simulated gastric ﬂuid
(SGF, pH= ~1.2). The TTH swelled progressively (Fig. 2d) and a
plateau of volume variation (Vt/V0) of 2.7± 0.15 was reached
after 6 days of incubation at 37 °C with an accompanying
decrease of the tensile properties at rupture. The tensile strength
and fracture strain of the TTH decreased to 74.1± 6.7 kPa and
12.2± 1.1, 62.4± 4.9 kPa and 10.1± 0.8, as well as 49.2± 5.7 kPa
and 8.8± 0.9 after incubated for 4, 8, and 12 days, respectively
(Supplementary Fig. 3a). The swelling also adversely affected the
maximum compressive stress of the TTH, which decreased to
2.24± 0.24MPa after 4 days of incubation in SGF (Fig. 2e). After
the initial decrease mainly attributed to swelling; however, the
maximum compressive stress of the TTH appeared to plateau
with further incubation, as conﬁrmed by a small change from
2.21± 0.18 to 2.07± 0.15MPa between 8 and 12 days of
incubation, respectively. It is worth mentioning that the
maximum gastric pressure in the fasted and fed states in humans
is known to range from 0.01 to 0.013MPa36, 37, which is far lower
than the maximum compressive stress of the TTH even following
incubation periods of up to 12 days, suggesting the potential
of these gels to resist gastric compression and achieve relative
long-term residence in the gastric cavity. We further measured
the dehydration and rehydration of TTHs and found that air-
drying effectively dehydrated and shrunk the gel signiﬁcantly
(Supplementary Fig. 3b). Scanning electron microscopy (SEM)
images displayed a uniform structure of the dried TTH
sample (Supplementary Fig. 4a). As expected, the TTH
could not dehydrate into a smaller size by lyophilization and a
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micro-porous structure was obtained for the lyophilized sample
(Supplementary Fig. 4b, c). We next measured the rehydration
of TTHs in SGF and found that a completely dehydrated
TTH with similar dimensions to a standard 000 capsule swelled to
a size greater than the diameter of the resting human pylorus
(12.8± 7.0 mm)38, 39 within 70 min (Fig. 2f), which is within the
50th percentile for gastric emptying in humans40. In addition, the
dehydrated TTH could swell to a size larger than the diameter of
pylorus within 15 min in a neutral pH approximating the
fed state or patients taking antacids or that can be achieved by
co-administration with antacids. The enhanced swelling is
attributed to the higher solubility of alginate in neutral pH than
in an acidic environment. We found that the adequately
rehydrated gel demonstrated a maximum compressive stress of
2.02± 0.18 MPa (Supplementary Fig. 5), demonstrating the
retention of toughness of TTHs after a cycle of complete
dehydration and subsequent rehydration. Alternatively, a TTH-
based encapsulation system encasing CaCO3 in an initial
form factor of a standard 000 capsule swelled to 27 mm within
30 min in SGF (Supplementary Fig. 6a, b). Similar strategies can
be applied for enabling ﬂotation of TTHs (Supplementary Fig. 6c).
Given the highly stretchable and tough characteristics,
various dosage forms compatible with ingestion and subsequent
gastric residence through size exclusion could be developed by
using TTHs.
Initial biocompatibility of TTHs was evaluated through in vitro
cell toxicity analysis. The gel was incubated in
cell culture medium across a wide range of concentrations from
0.2 to 50 mgml−1 at 37 °C for 24 h. The medium was then tested
for its cytotoxicity on multiple cell lines, including HeLa, Caco-2
(C2BBe1 clone), and HT29-MTX-E12 (Supplementary Fig. 7). No
signiﬁcant cytotoxicity was observed for the medium incubated
with the gel in any of these cell lines at the end of a 24 h culture
period. We next conducted extended cytotoxicity analysis by
culturing the TTHs with intestinal stem cells (ISCs) and
demonstrate excellent cytocompatibility of the TTHs with mouse
Lgr5+ stem cells over the course of 5 days (Supplementary
Fig. 8a). Furthermore, we showed that Lgr5+ stem cells could be
cultured on and within TTHs and these retained their ability of
multilineage differentiation to form organoids (Supplementary
Fig. 8b), supporting the biocompatibility and potential applica-
tion of TTHs serving as a substrate for organoid culture.
Triggerable properties of TTHs. We next investigated the
stimuli-responsiveness of TTHs by using ethylenediaminete-
traacetic acid (EDTA) and glutathione (GSH) as triggers of the
Ca2+ ion and disulﬁde crosslinks. Both EDTA and GSH have
been previously used in humans as treatments or supplements
with oral dosages of up to 6 and 5 g daily, respectively41, 42. In
addition, we recognized that both EDTA and GSH have been
used as additives in foods43, 44. To measure the triggerable
properties and potential boundaries set by EDTA and GSH found
in a human diet, TTHs were incubated at 37 °C with a range of
concentrations from 20 to 80 mM of EDTA and GSH well above
the concentrations found in food for various time intervals,
and then evaluated for compressive stress to characterize the
dissolution behavior of the gels. Interestingly and supporting the
selectivity of the EDTA and GSH combined triggering solution,
the TTH could not be dissolved by incubation with EDTA or
GSH alone even when incubation times were increased to 24 h
(Supplementary Fig. 9). These data support the ability to main-
tain a network by the remaining crosslinked single network
hydrogel and demonstrate that de-crosslinking of both alginate
and polyacrylamide networks are essential to dissolve the TTH.
The requirement for both EDTA and GSH for triggering supports
the likely sustained stability of the TTH in the presence of a
normal human diet. The dissolution of the gels was accelerated by
triggering with EDTA and GSH simultaneously. As shown in
Fig. 3a, the compressive stress of the TTH decreased rapidly from
373± 10 to 66.3± 5.8, 41.3± 3.9, and 16.7± 1.0 kPa after 1, 2,
and 4 h incubation in 20 mM of EDTA and 20 mM of GSH.
When the concentration of EDTA was increased to 40 mM while
the GSH was kept constant, the compressive stress of the TTH
reduced dramatically to 5.6± 0.04 kPa and the gel dissolved after
2 h of incubation. The TTH started to dissolve into a viscous
solution only after 1 h incubation with further increases of EDTA
to 80mM (Fig. 3b). In contrast, increases in GSH concentration
retarded the dissolution of the TTH (Supplementary Fig. 10),
suggesting that the carboxyl group at the C terminus of GSH
could disturb the formation of the ionic bond between the Ca2+
and the carboxyl groups in EDTA when excessive GSH was
present. Gel permeation chromatography (GPC) of the dissolved
TTH demonstrated two peaks with molecular mass of ~120 and
~200 kDa that corresponded to the dissociated alginate and
polyacrylamide chains, respectively, supporting the dissolution of
the TTH into free polymers (Supplementary Fig. 11). In vitro cell
viability assays veriﬁed the low cytotoxicity of these dissociated
free polymers against HeLa, Caco-2, and HT29 cell lines at the
end of a 24 h culture with concentrations up to 5 mgml−1
(Supplementary Fig. 12).
Having conﬁrmed in vitro the superior stimuli-responsiveness
of the gels, we next tested the in vivo dissolution of TTHs by
using a Yorkshire pig animal model, which has been previously
established for the evaluation of GI resident systems13, 45.
Yorkshire pigs weighing 45–55 kg have gastric and intestinal
anatomy and dimensions similar to humans46. TTH strips with
dimensions 50 mm × 10mm × 5mm were introduced endoscopi-
cally into the stomach. Pigs were administered a triggering
solution consisting of 0.5 L of EDTA (40 mM) and GSH (20 mM)
after deployment of the TTH strips. Control samples were
deployed into the stomach without the addition of the triggering
solution. The TTH strips were retrieved endoscopically after 1 h
in the gastric cavity. Strips retrieved from the control pigs
remained intact and retained a maximum compressive stress of
1.77± 0.15MPa (Supplementary Fig. 13), whereas the strips from
the treated pigs dissolved into viscous solution (Fig. 3c). To
further view the in situ dissolution of TTHs in stomach, large
TTH sheets, in the shape of an equilateral triangle (side length,
10 mm; thickness, 3 mm) were prepared and labeled with methyl
blue. These were triggered in situ with the EDTA/GSH solution
and endoscopic videography was used for image capture.
Endoscopic video revealed that the TTH sheets were triggered
to dissolve within 1 h in the gastric cavities of the treated pigs,
whereas the sheets in the control pigs remained intact (Fig. 3d).
These results support that TTHs can be triggered to
dissolve in vivo with biocompatible agents. We note that long-
term (>24 h) gastric resident systems present risks to patients
including GI mechanical obstruction and the inability to
discontinue a drug in the event of developing an allergic reaction
through non-invasive means. The ability to trigger the dissolution
of such systems is therefore essential for safe clinical implementa-
tion. The need for triggering is further ampliﬁed in resource-
constrained settings, where healthcare interventions-like
endoscopy and surgery may be largely limited and where the
inability to remove such systems could manifest in signiﬁcant
morbidity and mortality.
Gastric retentive drug delivery of TTHs. To evaluate the
mechanical integrity of TTHs and their potential application as
triggerable biomedical materials in gastric resident systems, we
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fabricated TTH prototypic gastric resident dosage forms.
These were evaluated for their gastric residence and integrity in
Yorkshire pigs. To evaluate the gastric retention and in vivo
integrity of TTHs, radiopaque capsule-like TTH dosage forms
with volumes of 22 ml (diameter, 2.8 cm; total length, 5 cm) were
designed and prepared by mixing barium sulfate with the pre-gel
solution immediately prior to polymerization. It was noted that
the signiﬁcant load of barium sulfate required for radiographic
visualization (20 wt%) manifested in slower swelling character-
istics than the TTHs (Supplementary Fig. 14). We therefore used
barium sulfate-containing TTHs in their hydrated states, which
enabled the retention by virtue of the size of the gel administered
and radiographic visualization by virtue of their barium content.
Four individual experiments in four different pigs were
performed and radiographs were taken approximately every
48–72 h to monitor the integrity of the dosage form, its anatomic
location, and any evidence of GI obstruction. Intact prototype
TTH systems were observed to achieve gastric residence of 7-9
days (Fig. 4a, b). TTHs remained stable in vitro in SGF
(>12 days) though in vivo breakage of TTHs was observed earlier
than this likely due to the compressive stress associated
with gastric motility, and potential de-crosslinking of alginate
network by exchange reactions with monovalent cations in the GI
environment47. Meanwhile, the disulﬁde bonds in polyacrylamide
network may be reduced by protein or peptide-associated thiols
though low-molecular weight thiols, GSH, and cysteine are only
present at a low level or even absent in human gastric ﬂuid48.
No intact devices were visualized outside of the gastric cavity,
supporting that device breakage ﬁrst occurred in the stomach
enabling their eventual passage out of the stomach. Once
device breakage occurred, the resulting fragments were visualized
in the intestines without evidence of intestinal obstruction
(Supplementary Fig. 15). Throughout the experiments, the ani-
mals were found to have normal eating and stooling patterns and
did not exhibit any signs of GI obstruction, either clinically or
radiographically.
Medication non-adherence is a major challenge for the
treatment of malaria and having the capacity to deliver drugs
in a single administration event has the potential to not only
enhance cure rates in acute malaria, but also decrease resistance
rates. To demonstrate a potential application of this system,
a gastric resident TTH dosage form containing lumefantrine,
a hydrophobic antimalarial drug, was selected to study the
drug loading and release from the TTH material. The
lumefantrine-loaded TTHs were similarly fabricated by mixing
drug powder with the prepolymerization solution just before
gelation. The degree of drug loading was easily controlled by
adjusting the feed ratio of drug. The maximum compressive stress
of the gel increased from 3.91± 0.31 to 5.43± 0.61MPa with the
increase of drug loading from 1 to 10 wt%, whereas the fracture
strain decreased from 14.7± 1.3 to 11.9± 1.5 and the tensile
strength remained around 180± 20 kPa (Supplementary Fig. 16).
In vitro release kinetics of the lumefantrine dosage forms were
characterized under predetermined sink conditions49 and the
results showed that the release of lumefantrine could be
controlled by tuning the drug loading. In vitro characterization
of the cumulative release of lumefantrine after 12-day incubation
in SGF increased from 8.3± 0.17 to 61± 3.7% with the decrease
of drug loading from 10 to 1 wt%, suggesting the diffusion of drug
was decreased as a function of reduced swelling of the TTH
associated with the increase in hydrophobicity of the gels
from the higher lumefantrine load (Supplementary Fig. 17a, b).
A ﬁrst-order rate equation was ﬁt to describe the rate of drug
release, and the release rate constants from gels loaded with 1, 5,
and 10% drug were found to be 11.1, 0.2, and 0.36 day−1,
respectively. It was noted that the post-polymerization puriﬁca-
tion affected the drug loading of TTHs prepared by mixing drug
powder with the prepolymerization solution. An alternative
strategy was demonstrated to avoid drug loss during the
preparation of drug-loaded TTHs by using post-polymerization
encapsulation. As shown in Supplementary Fig. 17c, we ﬁrst
prepared the puriﬁed TTH, then lyophilized and subsequently
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Fig. 4 Gastric retention and drug release of TTHs in pigs. a Representative X-ray images of a TTH device residing in the gastric cavity of a Yorkshire
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(the inset represents endoscopic image of the TTH device after 8 days retention in the gastric cavity). Plot of blood-drug concentration as a function of time
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barium sulfate for the gastric residence evaluation or loaded with lumefantrine for the pharmacokinetic study. Error bars show standard deviation (n= 3-4)
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rehydrated the TTH in the aqueous solution of drugs. In addition,
to evaluate the potential delivery of a range of molecules,
transport of model molecules across a range of molecular weights
was evaluated through TTHs. Speciﬁcally, insulin, rifampicin, and
dimethyl sulfoxide (DMSO) were observed to transport efﬁciently
through the TTH and showed size-dependent permeability that
increased from 0.016, 0.042 to 0.082 ml h−1 cm−2 with the
decrease of molecular weight from 5808, 823 to 78 Da
(Supplementary Fig. 18). To evaluate the release kinetics from
TTH in vivo, lumefantrine-loaded TTH systems in the same
dimensions and shape to the TTH system used for the gastric
retention and integrity studies were prepared. The pharmacoki-
netic studies were carried out by single administration of one
drug-loaded TTH device containing 960 mg of lumefantrine per
pig. The in vivo pharmacokinetics were signiﬁcantly extended
when administered in the form of TTH as compared to the
unformulated free drug control (Fig. 4c, d). After a single
administration of free lumefantrine, the drug was rapidly
cleared from blood with a rapid terminal elimination phase
(Supplementary Fig. 19). In contrast, a relative constant blood
drug concentration remained up to 4 days after a single
administration of the lumefantrine-loaded TTH device, support-
ing the potential for multi-day dosing using the TTH
drug delivery system. A pharmacokinetic model described by
ﬁrst-order rate equations was ﬁt to the data. The absorption rate
constant for both formulations was 1.17 day−1. The rate constant
for drug release in vivo was estimated to be 0.68 day−1, which is
~threefold higher than the in vitro release rate constant. This may
be because in vitro tests do not account for food effects and other
gastric secretions, which may signiﬁcantly affect drug release.
The elimination rate constants for the free drug was estimated
to be 1.17 day−1 and that apparent elimination rate constant
of the drug delivered in TTH was 0.68 day−1 indicating
delayed elimination.
In summary, we present a novel family of TTHs and
demonstrate their capacity for signiﬁcant dehydration and
rehydration. We further demonstrate their capacity to be
triggered to dissolve with the application of biocompatible
triggers. TTHs were evaluated for their stability and mechanical
integrity in a large animal model. A potential application in drug
delivery was also demonstrated with an extended release system
for lumefantrine. Preclinical studies will be required to translate
these systems for human application including further safety
studies and stress testing in other large animal models. In sum,
the TTHs described herein present three important points of
novelty from the hydrogel perspective: exceptional mechanical
properties: that can withstand in vivo gastric forces and achieve
long-term residence in the stomach of a large mammal;
remarkable triggerable properties: capable of on-demand dissolu-
tion; TTHs can be drug loaded and provide controlled drug
release. We believe that this combination of features makes TTHs
uniquely attractive for the development of advanced gastric
dosage forms for prolonged drug delivery, ingestible electronics,
and bariatric applications.
Methods
Materials. Acrylamide (A9099, ≥99%), N,N′-bis(acryloyl)cystamine (A4929),
ammonium persulfate (A3678, ≥98%), N,N,N′,N′-tetramethylethylenediamine
(T9281, 99%), sodium alginate (A2033, medium viscosity), calcium sulfate (C3771,
≥99%), methyl blue (M6900), barium sulfate (11844), L-GSH reduced (≥98%),
EDTA (≥99%), DMSO (D8418), sodium bicarbonate (NaHCO3, S5761), calcium
carbonate (CaCO3, ≥99%), and phosphate-buffered saline (PBS, pH 7.4) were
available commercially from Sigma-Aldrich and used as received unless otherwise
noted. Insulin was kindly provided by Novo Nordisk and labeled by Alexa-Fluor®
488. Lumefantrine and rifampicin were purchased from Hangzhou Hysen
Pharma Co., Ltd in China. Nanopure water (18 MΩ cm) was acquired by means of
a Milli-Q water ﬁltration system, Millipore (St. Charles). SGF (pH ~1.2) was made
by dissolving 2 g NaCl and 8.3 ml concentrated HCL in nanopure water and
adjusting to 1000 ml.
Mechanical characterization. The mechanical characterization in tension and
compression was performed on an Instron testing machine according to ASTM
standards D638 (tension) and D575 (compression). For tensile measurement,
specimens were loaded into the grips with a 50 N load cell and the gauge length
measured using a digital micrometer. Displacement was applied to the specimen at
a rate of 0.15 mm s−1 until samples ruptured. For compression measurement,
specimens were placed into a constrained loading compression jig with a 500 N
load cell and the gauge length measured using a digital micrometer.
Displacement was applied to the specimen at a rate of 0.05 mm s−1 until reaching
95% compressive strain. Force was converted into pressure (F/A) and displacement
into strain (ΔL/L).
High performance liquid chromatography (HPLC). HPLC measurement was
carried out on an Agilent 1260 Inﬁnity HPLC system equipped with a quaternary
pump, autosampler, thermostat, control module, and diode array detector as
described previously45 with minor modiﬁcations. The output signal was monitored
and processed using the ChemStation® software. Chromatographic separation was
carried out on a 50 mm × 4.6 mm EC-C18 Agilent Poroshell 120 analytical column
with 2.7 µm spherical particles, maintained at 40 °C. The optimized mobile phase
consisted of acetonitrile, methanol, and buffer (pH 3.5 adjusted with 0.1% formic
acid) (72:20:8, v/v) at ﬂow rate of 0.5 ml min−1 over a 10 min run time. The
injection volume was 4 µl, and the ultraviolet (UV) detection wavelength of 254 nm
was selected.
Liquid chromatography tandem-mass spectrometry. UPLC separation was
conducted on a Waters UPLC aligned with a Waters Xevo-TQ-SMS mass
spectrometer (Waters Ltd., UK) as described previously45 with minor protocol
modiﬁcations as follows. MassLynx 4.1 software was used for data acquisition and
analysis. Liquid chromatography separation was performed on an Acquity UPLC
CSH C18 (50 × 2.1 mm, 1.7 µm particle size) at 50 °C. The mobile phase consisted
of acetonitrile, 0.1% formic acid, and 10 mM ammonium formate was ﬂowed at a
rate of 0.6 ml min−1 using a time and solvent gradient composition. The initial
gradient (100%) was followed by a linear gradient (20%) over 0.25 min. Over the
next 1.25 min, the gradient was brought to 0% and held for 0.5 min and ﬁnally
brought back to the initial gradient of 100% over 0.25 min and held until the end of
the run for column equilibration. The total run time was 4 min and sample
injection volume was 2.5 µl. The mass spectrometer was operated in the multiple
reaction-monitoring mode. Sample introduction and ionization was ESI in the
positive ion mode. Stock solutions of lumefantrine and an internal standard
artemisinin were prepared in methanol at a concentration of 500 µg ml−1. A ten-
point calibration curve was prepared ranging from 2.5 to 2500 ng ml−1. Quality-
control samples were prepared in a similar procedure using an independent stock
solution at three concentrations (2.5, 25,and 250 ng ml−1). A measure of 200 µl of
internal standard 250 ng ml−1 was added to 100 µl of sample solution to cause
precipitation. Samples were vortexed and sonicated for 10 min and then placed in a
centrifuge for 10 min. A measure of 200 µl of solution was pipetted into a 96-well
plate containing 200 µl of water. Finally, 2.5 µl was injected into the Ultra
Performance Liquid Chromatography-electrospray ionization-MS system for
analysis.
SEM. Surface morphology of the dehydrated gels was observed using the JEOL
5600LV SEM. For visualization under SEM, samples were ﬁxed to aluminum stubs
with double-sided adhesive carbon conductive tape and subsequently sputter
coated with carbon using a Hummer 6.2 Sputter System.
GPC. Aqueous GPC was conducted on a Viscotek system (Malvern) equipped with
an isocratic pump Viscotek VE 1122 solvent delivery system, TDA 305 triple
detector array, and three TSK Gel GMPWxL column with guard column. The
system was equilibrated at 30 °C in pre-ﬁltered water containing 0.05 M NaNO3
with the ﬂow rate set to 1 ml min−1. Polymer solutions were prepared at a
concentration of about 0.5-5 mgml−1 and an injection volume of 200 μl was used.
Data collection and analysis were performed with ChemStation for LC (Agilent)
and OmniSEC v. 4,6,1,354 software (Malvern). The system was calibrated with poly
(ethylene oxide) standards (Sigma) ranging from 400 to 511,000 Da (Mp).
Preparation of TTHs. TTHs were prepared by a one-pot synthetic method.
Typically, acrylamide (3.60 g, 50.6 mmol), N,N′-bis(acryloyl)cystamine (13.2 mg,
0.051 mmol), ammonium persulfate (57.8 mg, 0.253 mmol), and sodium alginate
(600 mg) were dissolved into 30 ml nanopure water. N,N,N′,N′-tetra-
methylethylenediamine (29.4 mg, 0.253 mmol) and calcium sulfate (120 mg, 0.697
mmol) were added after a homogeneous solution was obtained. Calcium sulfate
was added as a suspension into the reaction mixture because of its limited water
solubility caused by its low dissociation constant. Although the association of Ca2+
with the carboxyl groups in alginate could accelerate the dissolution of calcium
sulfate, the complete dissolution took place overnight. Thus, the reaction mixture
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was presented as a free solution before subjecting it to polymerization even after all
the ingredients were added. The solution was carefully degassed and then quickly
poured into standard dumbbell die (ASTM D-638) molds. The gel was crosslinked
by heating to 50 °C for 1 h, then sitting in a humid box at room temperature for
another 24 h to stabilize the reaction. Afterwards, the resulted TTHs were
subjected to mechanical characterization. To prepare the TTH membrane for
permeability measurement, the pre-gel solution was poured into a glass mold
covered with a 3-mm-thick glass plate. To prepare a TTH-based ﬂoating system,
CaCO3 powder (5 wt%) was added into the reaction mixture just before poly-
merization. For in vivo dissolution study, the TTH membrane was labeled with
methyl blue by adding a drop of dye solution onto the top of the TTH membrane
and then covered by a glass plate and further incubated overnight. To prepare
radiopaque-labeled capsule-like TTHs, 20 ml pre-gel solution containing barium
sulfate (20 wt%) was added into a 50 ml CORNING CentriStarTM tube immedi-
ately prior to polymerization. The drug-loaded TTHs were similarly fabricated by
mixing lumefantrine powder with the prepolymerization solution just before
gelation, and the degree of drug loading was easily controlled from 1 to 10 wt% by
adjusting the feed ratio of drug. To prepare water soluble drug-loaded TTHs, the
puriﬁed TTH was lyophilized and subsequently rehydrated in the aqueous solution
of rifampicin (a water-soluble antibiotic).
Puriﬁcation of TTHs. To measure the unreacted ingredients in TTHs, the resulted
gel was cut into 1–2 mm pieces and sonicated in 10 volumes of water for 30 min.
The mixture was further incubated at 37 °C for 24 h on a shaker plate at 250 r.p.m.
After the addition of a certain volume of acetonitrile, the mixture was centrifuged
and the supernate was analyzed by HPLC. To purify the TTH, the obtained gel was
extensively extracted with 4 × 1000 ml water for 24 h. The same procedure
described above was performed to measure the unreacted ingredients in the
puriﬁed TTH.
Swelling and stability of TTHs in SGF. The swelling and stability of TTHs were
measured by incubating TTH samples in SGF at 37 °C and subsequent measuring
the volume as well as the maximum compressive stress. Typically, the cylindrical
TTH samples (diameter, 6.2 mm; length, 12 mm) were prepared by carrying out the
gelation reaction in a 3.5 ml VWR glass vial. The obtained gels were submerged in
50 ml GSH in a Corning CentriStarTM tube and then incubated at 37 °C on a
shaker plate at 250 r.p.m. After predetermined time intervals, the size of the
samples was measured by using a digital micrometer and compared with
initial volumes. Meanwhile, the TTH samples were also subjected to compression
measurement. Three replicates were conducted for each TTH sample.
Dehydration and rehydration of TTHs. The dehydration of TTHs was measured
by incubating TTH samples in air at 37 °C. Typically, the cylindrical TTH samples
(diameter, 6.2 mm; length, 12 mm) were placed in the oven set at 37 °C and the size
of the samples after predetermined incubation intervals was measured by using
a digital micrometer and compared with initial volumes. For rehydration
measurement, the dehydrated gel samples were submerged in 50 ml SGF in a
Corning CentriStarTM tube and incubated at 37 °C on a shaker plate at 250 r.p.m.
After different time intervals, the size of the samples was measured and compared
with initial volumes. Three replicates were conducted for each TTH sample. In a
control experiment, TTH samples were frozen at −20 °C and subsequently dried by
lyophilization.
Dissolution of TTHs with triggers. The dissolution of TTHs was studied by using
EDTA and GSH as triggers. Typically, the TTH were cut into 1 cm3-sized cubes
and submerged in 10 ml PBS (pH 7.4) containing EDTA and GSH with a range of
concentrations from 20 to 80 mM in a 20 ml VWR glass vial. Three replicates for
each time point and condition were incubated at 37 °C on a shaker plate at 250 r.p.
m. At each time point, the TTH cubes were subjected to compression measure-
ment. The TTH cubes incubated in either 20 mM of EDTA or GSH were used as
controls. To demonstrate the complete dissolution of TTHs into free polymer
chains, the triggered solutions were ﬁltered by a 0.2 µm ﬁlter and subsequently
injected into GPC. For cytotoxicity assay of the dissociated polymers, the triggered
solutions were transferred to dialysis tubes (MWCO, 10 kDa), then dialyzed against
pure water for 3 days to remove EDTA and GSH, and ﬁnally dried by
lyophilization.
Permeability measurement. The measurement of permeability of TTHs
was carried out on a Franz diffusion cell using a TTH membrane (thickness,
3 mm). 2 ml PBS (pH 7.4) containing 1 mgml−1 DMSO, rifampicin, or insulin was
added into the donor compartment of the cell and 12 ml fresh PBS was placed in
the acceptor compartment of the cell. At each time point, 0.4 ml was sampled from
the acceptor compartment and 0.4 ml fresh PBS was supplemented through the
sampling port of the cell. The concentration of DMSO and rifampicin of
the samples was recorded on a Perkin-Elmer Lambda ultraviolet-visible
spectrometer, and the UV absorbance calibration curve of DMSO in a range
from 6.25 to 100 µg ml−1 or rifampicin in a range from 1.56 to 100 µg ml−1 with a
correlation coefﬁcient >99.9% was used to determine the concentration. The
content of Alexa Fluor 488-labeled insulin was measured on an Inﬁnite M200Pro
(Tecan) reader (excitation, 490 nm; emission, 540 nm).
In vitro drug release. Individual 50 mg TTH cubes with lumefantrine content of 1,
5, or 10 wt% were used for long-term release studies. Typically, the TTH cubes
were submerged in 2 ml SGF in a 15 ml VWR centrifuge tube and then incubated
at 37 °C on a shaker plate at 250 r.p.m. At each time point, the release medium was
replaced by 2 ml fresh SGF and then frozen at −80 °C until analysis. The release
study was carried out for up to 12 days and the total drug release was measured by
HPLC using a linear standard curve of lumefantrine with a range of concentration
from 0.005 to 50 µg ml−1 and a correlation coefﬁcient >99.9%.
Cytotoxicity assay. The cytotoxicity assay of the dissociated polymers was
conducted by adding the polymers directly into the culture medium with a range of
concentrations from 0.02 to 5 mgml−1. For the TTH, the gel was incubated in the
culture medium with a range of dosage from 0.2 to 50 mgml−1 at 37 °C for 24 h.
The obtained medium was then tested for its toxicity toward cells. Cell lines were
purchased from ATCC and Public Health England for these experiments. To avoid
cross contamination, expanded cells were stored in individual containers. Regular
mycoplasma evaluations were performed of the cell culture environment and the
cell lines to ensure the absence of mycoplasma contamination. Cytotoxicity was
tested on HeLa, C2BBe1 (ATCC), and HT29-MTX-E12 cells (Public Health
England) by seeding them each in a 96-well plate at a density of 10,000 cells per
well as described previously13 with minor modiﬁcations. HeLa and HT29-MTX-
E12 cells were cultured in 100 µl Dulbecco’s modiﬁed Eagle medium (DMEM) (Life
Technologies) containing 1% non-essential amino acids (Life Technologies), 10%
fetal bovine serum (Life Technologies), and 1% penicillin-streptomycin solution
(Life Technologies) per well. C2BBe1 cells were cultured in the same medium, but
the 1% non-essential amino acids were replaced with 1% human insulin-
transferrin-selenium (Life Technologies). Cells were kept in culture for 3 days
before replacing the medium with 100 μl of the pre-prepared solutions as described
above. After 24 h, these solutions were replaced with 100 μl untreated media and
cytotoxicity was quantiﬁed by adding 10 µl alamarBlue reagent (Life Technologies)
to each well. The contents were mixed and then allowed to incubate at 37 °C for
1 h. Fluorescence was recorded on an Inﬁnite®M200Pro (Tecan) with excitation at
560 nm and emission at 590 nm. A positive control was provided by treating cells
with 70% ethanol for 1 hour prior to the cytotoxicity assay experiment. Cells that
were not subjected to any polymer-treated media provided a negative control. Cell
viability was calculated by the following equation: cell viability (%)= 100 ×
[Absorbance(sample)−Absorbance(positive control)]/[Absorbance(negative con-
trol)−Absorbance(positive control)].
Stem cell culture. Cell culture media (Advanced DMEM/F12 with N2, B27, and
N-acetylcysteine) containing growth factors (EGF, Noggin, and R-Spondin 1) and
small molecules (CHIR99021 and VPA) were used for stem cell culture. All animal
experiments were performed in accordance with protocols approved by the
Committee on Animal Care at MIT. Single mouse Lgr5-GFP ISCs were isolated
from Lgr5-EGFP-IRES-CreERT2 mice (Jackson Labs) as described previously50.
The isolated single Lgr5-GFP stem cells were cultured in Matrigel for 2 days to
form stem cell colonies before use. To evaluate the cytobiocompatibility of TTHs
against stem cells, the TTH dishes (thickness: 1 mm, diameter: 8 mm) were
cultured directly with Lgr5-GFP stem cell colonies in a 24-well plate for 5 days. To
test the ability of TTHs serving as a substrate for organoid culture, Lgr5-GFP stem
cell colonies were mixed with Matrigel and then placed on the lyophilized TTH
dishes in a 24-well plate. The plate was either placed in a 37 °C incubator directly
(for cell culture on the TTHs), or further incubated for 30 min on ice and
subsequently centrifuged at 300 × g for 2 min before placed in a 37 °C incubator
(for cell culture within the TTHs). Cells were cultured in stem cell culture media
for 3 days before switching to organoid culture media (by removing CHIR99021
and VPA to permit spontaneous differentiation of the stem cells) and further
cultured for another 4 days.
In vivo studies. All animal experiments were performed in accordance with
protocols approved by the Committee on Animal Care at MIT and as previously
described13, 45 with minor modiﬁcations. A large animal model, 45–55 kg York-
shire pigs, was chosen as its gastric anatomy similar to humans and is widely used
in evaluating devices in the GI space. Pigs were sedated with Telazol (tiletamine/
zolazepam) 5 mg kg−1, xylazine 2 mg kg−1, and atropine 0.05 mg kg−1, and/or iso-
ﬂurane (1-3% inhaled), and an endoscopic overtube (US Endoscopy) was placed in
the esophagus under endoscopic visual guidance during esophageal intubation. To
evaluate the TTH for its ability to be triggered to dissolve into solution with
biocompatible agents, the retrievable TTH strips and methyl blue-labeled large
TTH sheets were administered via the overtube into the stomach. PBS (0.5 l)
containing EDTA (40 mM), GSH (20 mM), and NaHCO3 (60 mM) was adminis-
tered via the overtube after the gastric placement of the TTH samples. Intra-gastric
endoscopy videography was used for image capture of the dissolution of the TTH
sheets. The TTH strips were retrieved endoscopically after 1 h in the gastric cavity.
Pigs that were not administered EDTA/GSH and therefore the strips and sheets
were only exposed to gastric ﬂuid were used as control experiments. To assess
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TTHs for the ability to achieve gastric retention, radiopaque barium sulfate-labeled
capsule-like TTHs were administered via the overtube into the gastric cavity (one
TTH device per pig). Radiographs were performed every 48–72 h to monitor the
integrity and transit of the devices as well as any radiographic evidence of bowel
obstruction or perforation. In vivo drug release experiments were performed with
dosage forms (one drug-loaded TTH device in their hydrated states containing 960
mg of lumefantrine per pig) in the same dimensions and shape to the barium
sulfate-loaded TTH device. Blood samples were obtained via cannulation of an
external mammary vein on the ventral surface of the pig at indicated time points,
most often time 0 min (prior to administration of the dosage form), 5 min, 15 min,
30 min, 2 h, 6 h, and then daily for a minimum of 5 days and then three times per
week. During the evaluation of the TTH systems for gastric residence and drug
delivery, the animals were monitored twice daily for any signs of abnormal feeding
and stooling patterns. In addition, the animals were monitored clinically for any
evidence of GI obstruction as well as radiographically every 48–72 h for evidence of
obstruction and/or perforation.
Modeling pharmacokinetic data. To determine the elimination rate constant and
half-life of the free lumefantrine, a one-compartment oral absorption model was ﬁt
to the pharmacokinetic data. The model is shown in Supplementary Fig. 19a. Using
this model, an equation was derived to describe the plasma concentration time
proﬁle.
Cp ¼ Dose kaV ka  keð Þ e
ke t  eka t  ð1Þ
To describe the pharmacokinetic proﬁle obtained from the lumefantrine-loaded
TTH device, a pharmacokinetic model described in Supplementary Fig. 19b was
used. An equation was obtained to describe the plasma concentration.
Cp ¼ Dose krelkaV
ekrel t
ka  krelð Þ ke  krelð Þ 
1
ka  ke
 
eke t
krel  ke 
eka t
krel  ka
  
ð2Þ
Data availability. The data supporting the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles and from the corre-
sponding authors on reasonable request.
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